Printer Friendly

Lung cancer drug hope; BRITAIN BRIEFLY.

A drug that frees the immune system to attack a devastating form of lung cancer has been shown to double the life expectancy of targeted patients.

Nivolumab is one of a new generation of immunotherapy drugs. The results, from a major trial involving patients who had already been treated for the most common form of lung cancer, were described by one expert as a "paradigm shift".

In the Phase III trial, the last step before a drug is licensed, the drug was found to be most effective in patients whose cancers produced higher levels of a protein PD-L1, which could lead to personalised treatment.

No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:South Wales Echo (Cardiff, Wales)
Date:Jun 1, 2015
Previous Article:PM 'must let cabinet have free Euro vote'.
Next Article:WE SAY.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters